Archon X Prize

Last updated
Archon Genomics X PRIZE presented by Express Scripts
X Prize genomics logo round.jpg
Awarded for"The US$ 10 million grand prize will be awarded to the team(s) able to sequence 100 human genomes within 30 days to an accuracy of 1 error per 1,000,000 bases, with 98% completeness, identification of insertions, deletions and rearrangements, and a complete haplotype, at an audited total cost of $1,000 per genome." [1]
CountryWorldwide
Presented by X PRIZE Foundation
Reward(s) US$10 million [2]
Website genomics.xprize.org

The Archon Genomics X PRIZE presented by Express Scripts for Genomics, the second X Prize offered by the X Prize Foundation, based in Playa Vista, California, was announced on October 4, 2006 stating that the prize of "$10 million will be awarded to the first team to rapidly, accurately and economically sequence 100 whole human genomes to an unprecedented level of accuracy." [2] The 30 day evaluation phase of the competition to begin on September 5, 2013, was canceled August 22, 2013 and this cancellation was debated on March 27, 2014. [3]

Contents

Goals and history

In November 2011 the prize goals were stated as: "The $10 million grand prize will be awarded to the team(s) able to sequence 100 human genomes within 30 days to an accuracy of 1 error per 1,000,000 bases, with 98% completeness, identification of insertions, deletions and rearrangements, and a complete haplotype, at an audited total cost of $1,000 per genome." [1]

The $10 million was donated by Canadian geologist and philanthropist Stewart Blusson, who co-discovered the Ekati Diamond Mine. The name "Archon" is the name of Blusson's company, which refers to the type of lithosphere beneath northern Canada. Upon cancellation, the money was returned to the Blussons because no Master Team Agreements were in place.

The Archon X Prize in genomics began as a joint effort of the X Prize Foundation and the J. Craig Venter Science Foundation. [1] [4] [5] The J. Craig Venter Science Foundation offered the $500,000 (US) Innovation in Genomics Science and Technology Prize in September 2003 aimed at stimulating development of less expensive and faster sequencing technology. To attract even more resources to this goal, Dr. Venter joined forces with the X Prize Foundation, wrapping his competition and prize purse into a later incarnation, The Archon Genomics X Prize presented by Express Scripts.

Test genomes

The 100 human genomes to be sequenced in this competition were donated by 100 centenarians (ages 100 or older) from all over the world, known as the 100 Over 100. Sequencing the genomes of the 100 Over 100 presented an unprecedented opportunity to identify those "rare genes" that protect against diseases, while giving researchers valuable clues to health and longevity. These centenarians’ genes would provide us with a window to the past, significantly impacting the future of healthcare. Although the contest is cancelled, the X PRIZE foundation collected blood samples and created cell-lines to preserve the DNA from more than 100 centenarians. Those genomes are expected to be sequenced nonetheless and put into an open data forum.

Teams

The only two pre-registered teams were Ion Torrent in Guilford, CT and Wyss Institute for Biologically Inspired Engineering in Boston, MA. These teams were announced 23-Jul-2012 and 3-Oct-2012. [3] [6]

Significance

The result was going to be the world's first "medical grade” genome, a critically needed clinical standard that would transform genomic research into usable medical information to improve patient diagnosis and treatment. This global competition was expected to inspire breakthrough genome sequencing innovations and technologies that would usher in a new era of personalized medicine.

The evaluation phase of the competition was officially set to begin on September 5, 2013, and conclude 30 days later on October 5, but was canceled August 22, 2013 because it was "outpaced by innovation". [7] A public debate concerning the validity and potential implications of the cancellation was published March 27, 2014. [3]

See also

Related Research Articles

<span class="mw-page-title-main">Craig Venter</span> American biotechnologist and businessman

John Craig Venter is an American biotechnologist and businessman. He is known for leading one of the first draft sequences of the human genome and assembled the first team to transfect a cell with a synthetic chromosome. Venter founded Celera Genomics, the Institute for Genomic Research (TIGR) and the J. Craig Venter Institute (JCVI). He was the co-founder of Human Longevity Inc. and Synthetic Genomics. He was listed on Time magazine's 2007 and 2008 Time 100 list of the most influential people in the world. In 2010, the British magazine New Statesman listed Craig Venter at 14th in the list of "The World's 50 Most Influential Figures 2010". In 2012, Venter was honored with Dan David Prize for his contribution to genome research. He was elected to the American Philosophical Society in 2013. He is a member of the USA Science and Engineering Festival's advisory board.

In genetics, shotgun sequencing is a method used for sequencing random DNA strands. It is named by analogy with the rapidly expanding, quasi-random shot grouping of a shotgun.

<span class="mw-page-title-main">Human genome</span> Complete set of nucleic acid sequences for humans

The human genome is a complete set of nucleic acid sequences for humans, encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria. These are usually treated separately as the nuclear genome and the mitochondrial genome. Human genomes include both protein-coding DNA sequences and various types of DNA that does not encode proteins. The latter is a diverse category that includes DNA coding for non-translated RNA, such as that for ribosomal RNA, transfer RNA, ribozymes, small nuclear RNAs, and several types of regulatory RNAs. It also includes promoters and their associated gene-regulatory elements, DNA playing structural and replicatory roles, such as scaffolding regions, telomeres, centromeres, and origins of replication, plus large numbers of transposable elements, inserted viral DNA, non-functional pseudogenes and simple, highly repetitive sequences. Introns make up a large percentage of non-coding DNA. Some of this non-coding DNA is non-functional junk DNA, such as pseudogenes, but there is no firm consensus on the total amount of junk DNA.

<span class="mw-page-title-main">Genomics</span> Discipline in genetics

Genomics is an interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.

<span class="mw-page-title-main">Comparative genomics</span>

Comparative genomics is a field of biological research in which the genomic features of different organisms are compared. The genomic features may include the DNA sequence, genes, gene order, regulatory sequences, and other genomic structural landmarks. In this branch of genomics, whole or large parts of genomes resulting from genome projects are compared to study basic biological similarities and differences as well as evolutionary relationships between organisms. The major principle of comparative genomics is that common features of two organisms will often be encoded within the DNA that is evolutionarily conserved between them. Therefore, comparative genomic approaches start with making some form of alignment of genome sequences and looking for orthologous sequences in the aligned genomes and checking to what extent those sequences are conserved. Based on these, genome and molecular evolution are inferred and this may in turn be put in the context of, for example, phenotypic evolution or population genetics.

XPRIZE foundation is a non-profit organization that designs and hosts public competitions intended to encourage technological development to benefit humanity. The XPRIZE mission is to bring about "radical breakthroughs for the benefit of humanity" through incentivized competition. It fosters high-profile competitions to motivate individuals, companies, and organizations across all disciplines to develop innovative ideas and technologies that help solve the world's grand challenges.

<span class="mw-page-title-main">DNA sequencing</span> Process of determining the nucleic acid sequence

DNA sequencing is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. It includes any method or technology that is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.

<span class="mw-page-title-main">Hamilton O. Smith</span> American biologist

Hamilton Othanel Smith is an American microbiologist and Nobel laureate.

<span class="mw-page-title-main">George Church (geneticist)</span> American geneticist

George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard. Through his Harvard lab Church has co-founded around 50 biotech companies pushing the boundaries of innovation in the world of life sciences and making his lab as a hotbed of biotech startup activity in Boston. In 2018, the Church lab at Harvard made a record by spinning off 16 biotech companies in one year. The Church lab works on research projects that are distributed in diverse areas of modern biology like developmental biology, neurobiology, info processing, medical genetics, genomics, gene therapy, diagnostics, chemistry & bioengineering, space biology & space genetics, and ecosystem. Research and technology developments at the Church lab have impacted or made direct contributions to nearly all "next-generation sequencing (NGS)" methods and companies. In 2017, Time magazine listed him in Time 100, the list of 100 most influential people in the world. In 2022, he was featured among the most influential people in biopharma by Fierce Pharma, and was listed among the top 8 famous geneticists of all time in human history. As of January 2023, Church serves as a member of the Bulletin of the Atomic Scientists' Board of Sponsors, established by Albert Einstein.

<span class="mw-page-title-main">Human Genome Project</span> Human genome sequencing programme

The Human Genome Project (HGP) was an international scientific research project with the goal of determining the base pairs that make up human DNA, and of identifying, mapping and sequencing all of the genes of the human genome from both a physical and a functional standpoint. It started in 1990 and was completed in 2003. It remains the world's largest collaborative biological project. Planning for the project started after it was adopted in 1984 by the US government, and it officially launched in 1990. It was declared complete on April 14, 2003, and included about 92% of the genome. Level "complete genome" was achieved in May 2021, with a remaining only 0.3% bases covered by potential issues. The final gapless assembly was finished in January 2022.

Stewart Lynn "Stu" Blusson, is a Canadian geologist, helicopter pilot, businessman, diamond magnate and philanthropist. He co-discovered billion-dollar Ekati Diamond Mine, 300 kilometres from Yellowknife, Northwest Territories, Canada. He is President of Archon Minerals Ltd. In 2002, Blusson donated key start-up funds necessary for Quest University Canada in Squamish, British Columbia. In 2006, Blusson donated $10 million for the Archon X PRIZE to develop a quick and inexpensive way to sequence the human genome. Blusson had a net worth of $660 million CDN in 2006.

Gerald Mayer Rubin is an American biologist, notable for pioneering the use of transposable P elements in genetics, and for leading the public project to sequence the Drosophila melanogaster genome. Related to his genomics work, Rubin's lab is notable for development of genetic and genomics tools and studies of signal transduction and gene regulation. Rubin also serves as a vice president of the Howard Hughes Medical Institute and executive director of the Janelia Research Campus.

The Centre for Applied Genomics is a genome centre in the Research Institute of The Hospital for Sick Children, and is affiliated with the University of Toronto. TCAG also operates as a Science and Technology Innovation Centre of Genome Canada, with an emphasis on next-generation sequencing (NGS) and bioinformatics support. Research at TCAG focuses on the genetic and genomic basis of human variability, health and disease, including research on the genetics of autism spectrum disorder and structural variation of the human genome. The centre is located in the Peter Gilgan Centre for Research and Learning in downtown Toronto, Canada.

<span class="mw-page-title-main">Whole genome sequencing</span> Determining nearly the entirety of the DNA sequence of an organisms genome at a single time

Whole genome sequencing (WGS), also known as full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.

There exist a number of competitions and prizes to reward distinguished contributions and to encourage developments in biotechnology.

Complete Genomics is a life sciences company that has developed and commercialized a DNA sequencing platform for human genome sequencing and analysis. This solution combines the company's proprietary human genome sequencing technology with its informatics and data management software to provide finished variant reports and assemblies at Complete Genomics’ commercial genome center in Mountain View, California.

<span class="mw-page-title-main">Transmission electron microscopy DNA sequencing</span> Single-molecule sequencing technology

Transmission electron microscopy DNA sequencing is a single-molecule sequencing technology that uses transmission electron microscopy techniques. The method was conceived and developed in the 1960s and 70s, but lost favor when the extent of damage to the sample was recognized.

<span class="mw-page-title-main">$1,000 genome</span> Era of predictive and personalized medicine

The $1,000 genome refers to an era of predictive and personalized medicine during which the cost of fully sequencing an individual's genome (WGS) is roughly one thousand USD. It is also the title of a book by British science writer and founding editor of Nature Genetics, Kevin Davies. By late 2015, the cost to generate a high-quality "draft" whole human genome sequence was just below $1,500.

Human Longevity, Inc. is a San Diego-based venture launched by Craig Venter and Peter Diamandis in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging. The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016. It has made deals with drug companies Celgene and AstraZeneca to collaborate in its research.

<span class="mw-page-title-main">Laurence H. Kedes</span> American academic (1937–2021)

Laurence H. Kedes was an American scientist in the fields of gene expression, genomics, and cellular differentiation. His first faculty position was at Stanford University (1970-1989), where he was promoted to full professor in the Department of Medicine and focused on basic molecular biology and gene expression. In 1988, the University of Southern California (USC) recruited Kedes to spearhead a campus-wide initiative to strengthen their molecular biology and genetics research programs. At USC, Kedes conceived and developed the Institute of Genetic Medicine, becoming its founding director (1989-2008) as well as the William Keck Professor (1988-2009) and Chair (1988-2002) of the Department of Biochemistry and Molecular Biology.

References

  1. 1 2 3 Kedes, L.; Campany, G. (2011). "The new date, new format, new goals and new sponsor of the Archon Genomics X PRIZE Competition". Nature Genetics. 43 (11): 1055–1058. doi: 10.1038/ng.988 . PMID   22030612.
  2. 1 2 "The Archon Genomics XPRIZE presented by Express Scripts -- Overview". Archived from the original on 2012-11-26. Retrieved 2012-05-31.
  3. 1 2 3 P Diamandis & G Church (27 Mar 2014). "Cancellation of the Archon Genomics XPRIZE: A Public Debate". Archived from the original on 21 April 2014.
  4. Kedes, L.; Liu, E.; Jongeneel, C. V.; Sutton, G. (2011). "Judging the Archon Genomics X PRIZE for whole human genome sequencing". Nature Genetics. 43 (3): 175. doi: 10.1038/ng0311-175 . PMID   21350493. S2CID   40592417.
  5. Kedes, L.; Liu, E. T. (2010). "The Archon Genomics X PRIZE for whole human genome sequencing". Nature Genetics. 42 (11): 917–918. doi:10.1038/ng1110-917. PMID   20980980. S2CID   32992934.
  6. "Archon Genomics X PRIZE Teams".
  7. P Diamandis (August 22, 2013). "Outpaced by Innovation: Canceling an XPRIZE". Huffington Post.